Class Action Firm Probes XOMA-Ligand Deal: Shareholders Question $39 Acquisition Price
Monteverde & Associates investigates XOMA Royalty's $39-per-share sale to Ligand Pharmaceuticals, questioning whether terms are fair to shareholders.
LGNDXOMAXOMAOXOMAPHLX+3acquisitionclass action